Abeona Therapeutics (ABEO) Q2 FY26 earnings call

Abeona Therapeutics continued its ZEVASKYN commercial rollout in Q2 FY26, expanding its QTC network to 7 sites and achieving NTAP status for the gene therapy. Despite logistical complexities and some manufacturing challenges leading to non-revenue generating treatments, the company reported strong revenue growth and is focused on increasing patient funnel and QTC efficiency. Management is refining reporting practices to align with commercial-stage companies.